To be honest I can't see any path to profitability: 1. Company loses >$3m a quarter with current contracts and running expenses 2. There are no new products 3. There are no profitable acquisitions in the pipeline 4. There is no mandated requirement for density reporting
All this couples to another CR in a year or two. Failure to capitalise will see competitors enter and this company will be struggling to survive. You must strike when the iron is hot and VHT has stood stale for the last 6 months or so, not capitalising on opportunities they said were being explored and are now hoping for FDA approval.
